AstraZeneca Reports 19% YOY Revenue Growth in Q3 2022
UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) released its Q3 2022 earnings report, showing...
FDA Approves Phase Ib Study for Jiangsu Yahong’s APL1401 in Ulcerative Colitis
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced that...
Baheal Partners with AstraZeneca for Commercial Rights to Onglyza
China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with AstraZeneca...
EQRx Shifts Strategy Amid FDA Feedback on China-Sourced Data
US-based EQRx Inc. (Nasdaq: EQRX), a biopharma originally established with the aim of “radically” disrupting...
Peking University Study Identifies Liver Cancer Immune Microenvironment Subtypes
Researchers at Peking University have uncovered several subtypes in the tumor immune microenvironment (TIME) relevant...
CDE Prioritizes Review for Jiedi Pharma’s Mitotane and Other Key Drugs
The Center for Drug Evaluation (CDE) website indicates that market filings for several key drugs,...
CanSino Biologics’ Inhalable COVID-19 Vaccine Authorized in Morocco
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received emergency use...
Luye Pharma’s Biosimilar LY06006/BA6101 Approved for Osteoporosis Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from...
Lundbeck’s Eptinezumab Launches in Boao Lecheng for Migraine Treatment
Lundbeck’s (FRA: LDBB) Eptinezumab has been launched in the Boao Lecheng International Medical Tourism Zone,...
Novartis Partners with Alibaba Health to Enhance Patient Medication Accessibility
The 5th China International Import Expo (CIIE) saw the announcement of a partnership between Swiss...
RemeGen’s Telitacicept Set for Breakthrough Therapy Designation in Myasthenia Gravis
The Center for Drug Evaluation (CDE) website indicates that China-based RemeGen Co., Ltd’s (HKG: 9995,...
Harbour BioMed and Moderna Ink Licensing Deal for Oncology Immunotherapies
Harbour BioMed (HKG: 2142), a biotech company with operations in the United States, the Netherlands,...
CStone’s PD-L1 Inhibitor Sugemalimab Achieves Primary Endpoint in Gastric Cancer Study
China-based CStone Pharmaceuticals (HKG: 2616) has announced that its GEMSTONE-303 study for the programmed death-ligand...
BeiGene’s Brukinsa Receives Marketing Approval in Brazil
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that it has...
Fujian Cosunter Receives Multiple Patents for Cancer and Hepatitis Drugs
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the receipt of multiple patents...
Sinocelltech’s SCTV01E Vaccine Receives NMPA Approval for Phase II Study
China-based Sinocelltech Group Ltd (SHA: 688520) has announced that it has received approval from the...
3SBio’s Thrombopoietin Study in Pediatric ITP Reaches Primary Endpoint
China-based 3SBio Inc. (HKG: 1530) has announced that its multi-center, randomized, double-blind, placebo-controlled study assessing...
Zenas BioPharma Completes $118M Series B Financing to Advance Obexelimab
Autoimmune disease drug developer Zenas BioPharma, which is based in the US and China, has...
LianBio Initiates Phase I Study of SHP2 Inhibitor BBP-398 in China
Sino-US biotech LianBio has announced the first patient dosing in a Phase I clinical study...
Innovex Medical Files for IPO in Hong Kong to Boost Product Development
Innovex Medical Co., Ltd, a non-vascular interventional surgery solutions provider based in Shanghai, has filed...